Maplirpacept

DRUG5 trials

Sponsors

Pfizer Inc., Mayo Clinic, Pfizer

Conditions

Diffuse Large B-Cell LymphomaMultiple MyelomaNon-Hodgkin LymphomaRecurrent ALK Positive Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Phase 1

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

TerminatedNCT05626322

PfizerDiffuse Large B-Cell Lymphoma

Start: 2023-08-04End: 2025-05-01Updated: 2025-09-05

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

Active, not recruitingNCT05675449

PfizerMultiple Myeloma

Start: 2022-12-14End: 2028-02-29Target: 59Updated: 2026-03-27

A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China

CompletedNCT05896774

PfizerMultiple Myeloma, Non-Hodgkin Lymphoma

Start: 2023-06-28End: 2024-11-06Updated: 2024-11-20

C4971006: A PHASE 1b/2, OPEN-LABEL STUDY OF PF-07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED, SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION

CompletedCTIS2022-502822-41-00

Pfizer Inc.Relapsed/Refractory Diffuse Large B Cell Lymphoma

End: 2025-08-01Target: 34Updated: 2025-04-30

Phase 2

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Active, not recruitingNCT05507541

Mayo ClinicRecurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation +25

Start: 2023-04-19End: 2027-07-30Updated: 2025-08-29

Related Papers

Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Blood2024-11-056 citations

A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Tafasitamab and Lenalidomide in People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood2023-11-021 citations